Palliative Oncology & Psilocybin-Assisted Therapy Market
完整報告名稱與涵蓋範圍
Palliative Oncology & Psilocybin-Assisted Therapy Market Size, Share & Trends Analysis Report, By Therapy Component (Psilocybin and Psilocybin Analog Drug Products, Psychotherapy Support and Session Delivery Services, Adjunctive Palliative Psychopharmacology), By Indication (Cancer-Related Depression and Anxiety, Existential and End-of-Life Distress, Demoralization and Adjustment Disorders in Serious Illness), By Care Setting (Cancer Centers and Palliative Care Units, Hospice and Community Palliative Services, Licensed Psychedelic Therapy Clinics), By Development Stage, By Region, and Segment Forecasts, 2026-2035
報告摘要
The palliative oncology and psilocybin-assisted therapy market covers psilocybin and psilocybin-analog drug products, the structured psychotherapy and session delivery services that accompany them and adjunctive palliative psychopharmacology, applied to depression, anxiety, existential distress and demoralization in people with cancer and other serious illnesses. Conventional antidepressants prescribed in oncology are analysed as the incumbent standard but excluded from revenue. Because psilocybin therapy remains investigational in most jurisdictions, the forecast separates current expanded-access, jurisdictional-access and trial-related revenue from product revenue contingent on regulatory approval.
Momentum comes from randomized trials showing rapid and durable reductions in cancer-related depression and anxiety after one or two supervised sessions, from breakthrough therapy designations, and from regulated access programs in Australia, Oregon, Colorado and several other jurisdictions. Late-stage trials in treatment-resistant depression provide the regulatory path most likely to open first, with palliative oncology following through label expansion or supplemental programs. The service model, which requires trained facilitators and multi-hour monitored sessions, is the principal cost and scalability question, and reimbursement frameworks are only beginning to emerge.
North America and Australia lead access and trial activity, with Europe and Canada expanding regulated pathways. Competition involves psychedelic drug developers, specialist therapy clinic networks and non-profit institutes sponsoring pivotal research.
The InsightAce study supplies US$ forecasts for all therapy component, indication, care setting and development stage and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Snapshot
Chapter 4. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Therapy Component Estimates & Trend Analysis
5.1. Therapy Component & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapy Component:
5.2.1. Psilocybin and Psilocybin Analog Drug Products
5.2.2. Psychotherapy Support and Session Delivery Services
5.2.3. Adjunctive Palliative Psychopharmacology
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Cancer-Related Depression and Anxiety
6.2.2. Existential and End-of-Life Distress
6.2.3. Demoralization and Adjustment Disorders in Serious Illness
Chapter 7. Market Segmentation 3: By Care Setting Estimates & Trend Analysis
7.1. Care Setting & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Care Setting:
7.2.1. Cancer Centers and Palliative Care Units
7.2.2. Hospice and Community Palliative Services
7.2.3. Licensed Psychedelic Therapy Clinics
Chapter 8. Market Segmentation 4: By Development Stage Estimates & Trend Analysis
8.1. Development Stage & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
8.2.1. Investigational and Expanded Access
8.2.2. Approved and Reimbursed
Chapter 9. Palliative Oncology & Psilocybin-Assisted Therapy Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Compass Pathways plc
11.2. Usona Institute
11.3. Cybin Inc.
11.4. Psyence Biomedical Ltd.
11.5. MindMed Inc.
11.6. Beckley Psytech Ltd. (atai Beckley)
11.7. Reunion Neuroscience Inc.
11.8. Filament Health Corp.
11.9. Sunstone Therapies
11.10. Numinus Wellness Inc.
11.11. Clairvoyant Therapeutics Inc.
11.12. Optimi Health Corp.
11.13. PsyBio Therapeutics
11.14. Otsuka Pharmaceutical Co., Ltd.
11.15. Johnson & Johnson (Spravato Palliative Use)
圖表清單 List of Tables & Figures
Table 1. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue Forecast by Therapy Component, 2026-2035 (US$ Mn)
Figure 1. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Segmentation and Scope Overview
Table 2. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Share by Therapy Component, 2026 & 2035
Table 3. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue Forecast by Care Setting, 2026-2035 (US$ Mn)
Figure 3. Regulatory Access Pathways for Psilocybin Therapy by Jurisdiction, 2026
Table 4. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 4. Late-Stage Psilocybin Pipeline and Expected Approval Timeline
Table 5. Global Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Palliative Oncology & Psilocybin-Assisted Therapy Growth Opportunity Analysis
Table 6. North America Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Palliative Oncology & Psilocybin-Assisted Therapy Market Participants
Table 7. Europe Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Palliative Oncology & Psilocybin-Assisted Therapy Market
Table 8. Asia Pacific Palliative Oncology & Psilocybin-Assisted Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Session Delivery Cost Structure and Facilitator Capacity Requirements
Table 9. Strategic Developments of Leading Palliative Oncology & Psilocybin-Assisted Therapy Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們